Efficacy and cost-effectiveness of darbepoetin alfa once every 4 weeks versus continuous erythropoietin receptor activator once every 4 weeks for anemia correction in patients with chronic kidney disease not on dialysis

• Main Authors: Geo Neul Park (Author), Kyung Ho Lee (Author), Ji Eun Moon (Author), Soo Jeong Choi (Author), Moo Yong Park (Author), Jin Kuk Kim (Author), Byung Chul Yu (Author)
• Format: Book
• Published: The Korean Society of Nephrology, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background For anemia management in patients with chronic kidney disease not on dialysis, darbepoetin alfa (DA), which has a shorter half-life but is more inexpensive than continuous erythropoietin receptor activator (CERA), is preferred in Korea. This study evaluated the efficacy, safety, and cost-...